Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Vlot

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Haematologica|May 1, 1990
Thrombotic thrombocytopenic purpura. Clinical course and response to therapy in seven patientsA J Vlot, R J Hené, J J Marx
Nederlands Tijdschrift Voor Geneeskunde|March 3, 1990
[Thrombotic thrombocytopenic purpura: a benign disease with a very severe acute phase]A J Vlot, R J Hené, J J Sixma
Thrombosis and Haemostasis|April 8, 1998
Factor VIII and von Willebrand factorA J Vlot, S J Koppelman, B N Bouma, et al.
Lancet (London, England)|August 15, 2001
Antibodies that stop the adrenals in their tracksA J Vlot, A J van der Molen, M J Muis, et al.
The American Journal of Medicine|April 12, 2000
Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VIIA J Vlot, E Ton, A J Mackaay, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 4, 2021
[Confusion and abdominal pain after COVID-19 vaccination]K Beelen, J Schouten, M C de Boer, et al.
Blood|June 1, 1995
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factorA J Vlot, S J Koppelman, M H van den Berg, et al.
Thrombosis and Haemostasis|February 11, 2000
The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group AA J Vlot, E P Mauser-Bunschoten, A G Zarkova, et al.
Blood|March 1, 1996
Kinetics of factor VIII-von Willebrand factor associationA J Vlot, S J Koppelman, J C Meijers, et al.
Blood|March 15, 1996
Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein CS J Koppelman, M van Hoeij, T Vink, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Haematologica|May 1, 1990
Thrombotic thrombocytopenic purpura. Clinical course and response to therapy in seven patientsA J Vlot, R J Hené, J J Marx
Nederlands Tijdschrift Voor Geneeskunde|March 3, 1990
[Thrombotic thrombocytopenic purpura: a benign disease with a very severe acute phase]A J Vlot, R J Hené, J J Sixma
Thrombosis and Haemostasis|April 8, 1998
Factor VIII and von Willebrand factorA J Vlot, S J Koppelman, B N Bouma, et al.
Lancet (London, England)|August 15, 2001
Antibodies that stop the adrenals in their tracksA J Vlot, A J van der Molen, M J Muis, et al.
The American Journal of Medicine|April 12, 2000
Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VIIA J Vlot, E Ton, A J Mackaay, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 4, 2021
[Confusion and abdominal pain after COVID-19 vaccination]K Beelen, J Schouten, M C de Boer, et al.
Blood|June 1, 1995
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factorA J Vlot, S J Koppelman, M H van den Berg, et al.
Thrombosis and Haemostasis|February 11, 2000
The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group AA J Vlot, E P Mauser-Bunschoten, A G Zarkova, et al.
Blood|March 1, 1996
Kinetics of factor VIII-von Willebrand factor associationA J Vlot, S J Koppelman, J C Meijers, et al.
Blood|March 15, 1996
Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein CS J Koppelman, M van Hoeij, T Vink, et al.
Pageof 2